Atea Pharmaceuticals Competitors

AVIR -  USA Stock  

USD 27.72  0.59  2.17%

Atea Pharmaceuticals competes with Equillium, Diamedica Therapeutics, Denali Therapeutics, Dicerna Pharmaceutic, and Design Therapeutics; as well as few others. The company conducts business under null sector and is part of null industry. Analyzing Atea Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Atea Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Atea Pharmaceuticals competition on your existing holdings. Please continue to Atea Pharmaceuticals Correlation with its peers.

Search Competition 

 
Refresh
As of 09/17/2021, Return on Invested Capital is likely to grow to 0.07, while Return on Investment is likely to drop (20.28) . Atea Pharmaceuticals Total Assets are relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Total Assets of 863.63 Million. As of 09/17/2021, Current Assets is likely to grow to about 931.6 M, while Net Current Assets as percentage of Total Assets are likely to drop 102.91.

Specify up to 10 symbols:

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Atea Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Atea Pharmaceuticals in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
23.5326.8330.13
Details
Intrinsic
Valuation
LowReal ValueHigh
24.5334.9538.25
Details
4 Analysts
Consensus
LowTarget PriceHigh
37.0046.5056.00
Details
Earnings
Estimates (3)
LowProjected EPSHigh
0.050.841.27
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Atea Pharmaceuticals. Your research has to be compared to or analyzed against Atea Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Atea Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Atea Pharmaceuticals.

Atea Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Atea Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Atea Pharmaceuticals and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Atea Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Atea Pharmaceuticals Competition Risk-Adjusted Indicators

Nowadays, there is a big difference between Atea Pharmaceuticals stock performing well and Atea Pharmaceuticals company doing well compared to the competition. There are way too many exceptions to the normal that investors can tell for sure what's good or bad unless they analyze Atea Pharmaceuticals' multiple risk-adjusted performance indicators. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
EQ
 2.92  0.05  0.01  0.05  3.42  0.0103 (3.39)  7.93 (5.99)  30.83 
DMAC
 4.21 (0.93)  0.00  4.63  0.00 (0.15)  0.00  6.70 (7.87)  35.72 
DNLI
 2.12 (0.46)  0.00 (0.83)  0.00 (0.15)  0.00  4.03 (4.75)  18.67 
DRNA
 2.53 (0.67)  0.00 (2.19)  0.00 (0.15)  0.00  4.11 (5.30)  32.25 
DSGN
 2.98 (0.46)  0.00 (0.50)  0.00 (0.11)  0.00  6.19 (7.81)  25.12 
DTIL
 2.80  0.25  0.07  0.22  3.39  0.07 (3.16)  6.58 (5.15)  24.86 
DVAX
 3.50  0.83  0.18  1.09  4.21  0.18 (4.13)  7.82 (6.89)  29.34 
DYAI
 4.71  0.84  0.17  0.28  4.44  0.11 (6.41)  12.24 (8.78)  61.31 
EDIT
 3.86  0.95  0.24  0.64  3.60  0.18 (4.69)  9.42 (5.15)  35.18 
EDSA
 2.21  0.06  0.01 (0.05)  2.53  0.0125 (2.57)  4.40 (4.54)  17.46 

Cross Equities Net Income Analysis

Select Fundamental

201020112012201320142015201620172018201920202021
EQ
(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(25.6 M)(29.8 M)(32.2 M)
DMAC
(2.2 M)(2.2 M)(2.2 M)(2.2 M)(2.2 M)(2.2 M)(2.2 M)(4.3 M)(5.7 M)(10.6 M)(12.3 M)(12.6 M)
DNLI
(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(86.7 M)(88.2 M)(36.2 M)(197.6 M)71.1 M76.8 M
DRNA
(8.6 M)(8.6 M)(10.1 M)(18.5 M)(47.9 M)(62.8 M)(59.5 M)(60.2 M)(88.9 M)(120.5 M)(112.7 M)(115.7 M)
DSGN
(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(8.3 M)(8.5 M)
DTIL
(21.1 M)(21.1 M)(21.1 M)(21.1 M)(21.1 M)(21.1 M)(21.1 M)(21.1 M)(46 M)(92.9 M)(109 M)(111.9 M)
DVAX
(57.3 M)(48.6 M)(69.9 M)(66.7 M)(90.7 M)(106.8 M)(112.4 M)(95.2 M)(158.9 M)(152.6 M)(75.2 M)(81.2 M)
DYAI
(3.6 M)(3.6 M)(3.6 M)(3.6 M)(3.6 M)(3.6 M)(3.6 M)(2.1 M)(5.7 M)(8.3 M)(9.3 M)(9.6 M)
EDIT
(13.7 M)(13.7 M)(13.7 M)(13.7 M)(13.7 M)(72.9 M)(97.2 M)(120.3 M)(110 M)(133.7 M)(116 M)(125.1 M)
EDSA
(2.8 M)(2.8 M)(2.8 M)(2.8 M)(2.8 M)(5 M)(5 M)(6.4 M)(1.9 M)(6.4 M)(1.9 M)(2 M)

Atea Pharmaceuticals and related stocks such as Equillium, Diamedica Therapeutics, Denali Therapeutics, Dicerna Pharmaceutic, Design Therapeutics, Precision Biosciences, Dynavax Technologies, Dyadic International, Editas Medicine, and Edesa Biotech Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Atea Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Atea Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.

Atea Pharmaceuticals Competitive Analysis

The better you understand Atea Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Atea Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Atea Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
AVIR
EQ
DMAC
DNLI
DRNA
DSGN
DTIL
DVAX
DYAI
EDIT
 2.17 
 27.72 
Atea Pharmaceuticals
 8.94 
 5.40 
Equillium
 10.37 
 3.63 
Diamedica
 2.26 
 51.83 
Denali
 1.17 
 21.14 
Dicerna
 1.19 
 16.17 
Design
 3.82 
 12.10 
Precision
 3.60 
 13.92 
Dynavax
 1.52 
 5.35 
Dyadic
 0.34 
 60.79 
Editas
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Stock Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Number of Shares Shorted
Shares Owned by Insiders
Current Ratio
Profit Margin
EBITDA
Operating Margin
Current Valuation
Cash Flow from Operations
Retained Earnings
Current Asset
Beta
Price to Book
Shares Outstanding
Total Debt
Return On Equity
Price to Earning
Z Score
Shares Owned by Institutions
Return On Asset
Book Value Per Share
Cash and Equivalents
Current Liabilities
Price to Earnings To Growth
Total Asset
Short Ratio
Price to Sales
Market Capitalization
Cash per Share
Net Income
Earnings Per Share
Debt to Equity
Revenue
Working Capital
Gross Profit
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Atea Pharmaceuticals Competition Performance Charts

Complement your Atea Pharmaceuticals position

In addition to having Atea Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Electrical Equipment Thematic Idea Now

Electrical Equipment
Electrical Equipment Theme
Fama and French focuses on testing asset pricing under different economic assumptions. Electrical Equipment theme has 31 constituents.
View All  Next Launch Electrical Equipment
Please continue to Atea Pharmaceuticals Correlation with its peers. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.